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The aim was to compare the psychological impact of a multidisciplinary specialist genetics service with surgical provision in
women at high risk and those at lower risk of familial breast cancer. Women (n=735) were randomized to a surgical
consultation with (trial group) or without (control group) specialist genetic risk assessment and the possible offer of
presymptomatic genetic testing. Participants completed questionnaires before and immediately after the consultation to assess
anxiety, cancer worry, perceived risk, interest in genetic testing and satisfaction. Responses of subgroups of women stratiﬁed
by clinicians as low, moderate, or high risk were analyzed. There were no signiﬁcant main effects of study intervention on any
outcome variable. Regardless of risk information, there was a statistically signiﬁcant reduction in state anxiety (P50.001).
Reductions in cancer worry and perceived risk were signiﬁcant for women at low or moderate risk (P50.001) but not those
at high risk, and satisfaction was signiﬁcantly lower in the high risk group (P50.001). In high risk women who received
specialist genetic input, there was a marginally signiﬁcant trend towards increased perceived risk. The effect of risk information
on interest in genetic testing was not signiﬁcant. Breast care specialists other than geneticists might provide assessments of
breast cancer risk, reassuring women at reduced risk and targeting those at high risk for specialist genetic counselling and
testing services. These ﬁndings are discussed in relation to the existing UK Calman-Hine model of service delivery in cancer
genetics.
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Breast cancer is the most common cancer in women in the UK.
Advances in knowledge of the genetic basis of breast cancer have
led to increased public awareness of the importance of a family
history in determining susceptibility to the disease. However, the
vast majority of breast cancer cases arise sporadically, with no clear
familial genetic component. Known inherited gene mutations are
implicated in around 5–10% of cases (King et al, 1993), therefore
presymptomatic genetic testing is not appropriate for the majority
of women with a family history of breast cancer. In recent years
there has been an increase in referrals to specialist cancer genetics
services which offer genetic risk assessment and counselling and, in
the small proportion of those identiﬁed as high risk, genetic testing
for cancer susceptibility (Campbell et al, 1995; Evans et al, 1994).
Referrals to these services include not only those at high genetic
risk, but also the much more frequent cases where risk is slightly
increased or not signiﬁcantly different from that of the general
population. However, there is a lack of evidence regarding appro-
priate models of cancer genetics service provision for women who
are at different levels of familial breast cancer risk.
Previous research illustrates the high level of interest in genetic
testing among at-risk populations (Durfy et al, 1999; Jacobsen et
al, 1997; Lerman et al, 1995). Although genetic testing is often
regarded as the primary endpoint of cancer risk assessment
services, lower risk individuals can gain useful information and
support from these services without such testing (Kelly, 1999).
Many women with a family history of breast cancer perceive them-
selves to be at high risk (Evans et al, 1993; Kash et al, 1992; Lerman
et al, 1993) and may seek genetic advice in order to reduce anxiety
about personal risk (Brain et al, 2000a). Indeed, perceptions of
increased risk and associated anxiety may be more important than
actual risk in motivating individuals to approach cancer genetics
services (Lerman et al, 1994; Petersen et al, 1999). Therefore
important aims of genetic risk assessment and counselling are to
communicate accurate risk information and alleviate anxiety.
There are clear resource implications of providing widespread
cancer genetics services and an urgent need for evidence regard-
ing appropriate service provision for women at high risk and
those at lower risk of breast cancer (Report by the expert advi-
sory group on cancer to the Chief Medical Ofﬁcers of England
and Wales, 1995; Report of a working group on cancer genetics
services, 1998). The present study addresses this issue by
comparing the psychological impact of specialist genetic risk
assessment with that of standard surgical provision on women
identiﬁed as being at different levels of breast cancer risk. An
earlier report of this randomized trial found few psychological
effects of receiving specialist genetic assessment compared with
surgical provision, with reductions in anxiety regardless of
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al, 2000b). In the current paper, we report secondary analyzes
of these data in order to examine the impact of specialist genetic
versus surgical assessment on primary outcomes (anxiety, worry
and perceived risk) and secondary outcomes (interest in genetic
testing and satisfaction) in subgroups of women stratiﬁed as
low, moderate, or high risk. It was predicted that, regardless of
their group allocation, anxiety and perceived risk would be high-
er in women found to be at high risk compared to those at
lower risk. It was further predicted that high risk women would
be less satisﬁed with their consultation and that interest in genet-
ic testing would remain high in high risk women but would
decrease in those at lower risk.
MATERIALS AND METHODS
Full ethical approval was granted on the basis that, at the time the
study was initiated, genetic risk assessment and possible presymp-
tomatic testing were not available for families at increased risk of
breast cancer in Wales. At that time, standard practice involved
surgical-led management. A consecutive series of women identiﬁed
by their general practitioner or local breast surgeon as having a
family history of breast cancer were referred to the TRACE project
(Trial of genetic assessment in breast cancer) during an 18-month
period from 1996 to 1997. A family history of breast cancer was
deﬁned as a ﬁrst-degree female relative diagnosed with breast
cancer before age 50 years, a ﬁrst-degree female relative with bilat-
eral breast cancer at any age, two or more ﬁrst-degree relatives with
breast cancer, or a ﬁrst- and second-degree relative with breast
cancer. Women were excluded from the trial if they had a personal
history of breast cancer, had previously received genetic counsel-
ling, or were not resident in Wales. Written informed consent
was obtained from each participant. The consent form afﬁrmed
patient conﬁdentiality and the right to withdraw from the research
study at any time without affecting medical care. Further details of
the referral procedure are reported in Brain et al (2000a).
Figure 1 illustrates the ﬂow of patients through the trial. One
thousand women were referred and sent a baseline questionnaire.
Seven hundred and thirty-ﬁve randomly assigned participants in
both study groups were given a questionnaire to complete after
clinic, which was returned by 655 women. Factors associated with
participation bias are reported in an earlier article (Brain et al,
2000b). The study was powered to detect a 0.5 difference at the
5% level between risk groups in primary outcomes.
At baseline, participants completed the state scale of the State-
Trait Anxiety Inventory (Spielberger, 1983), the Breast Cancer
Worry scale (Lerman et al, 1991a,b), and two scales on which they
indicated their level of perceived risk and interest in obtaining
genetic testing. The Breast Cancer Worry scale is a 6-item scale that
assesses frequency of concerns about developing breast cancer and
the impact of cancer worry on mood and daily functioning. It has
high internal consistency (Cronbach’s alpha=0.86). Higher worry
scores have been associated with inappropriate adherence to
mammography screening (Lerman et al, 1991b) and breast self-
examination (Brain et al, 1999) in at-risk women. Two items
derived from previous research (Champion, 1984; Fallowﬁeld et
al, 1990; Lerman et al, 1991a) were used to assess perceived risk
(alpha=0.71). Interest in genetic testing was assessed using three
categories (1=want a genetic test, 2=do not want a genetic test,
3=uncertain). Immediately after clinic, participants completed the
same measures along with the 12-item Satisfaction with Genetic
Counselling Questionnaire (Shiloh et al, 1990). This assesses three
dimensions of patient satisfaction: (i) instrumental (the extent to
which the patient believes the doctor has the required skills and
gives the required treatment and reassurance) (alpha=0.69), (ii)
affective (satisfaction with personal qualities of the doctor)
(alpha=0.79), and (iii) procedural (satisfaction with administrative
procedures such as waiting time) (alpha=0.65).
Individual randomization to the trial clinic or control clinic was
based on a computer-generated sequence of random group assign-
ments and took place on receiving the completed baseline
questionnaire. In order to minimize response bias, there was no
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Referred to trial (n=1000)
Not randomized (n=260)
Randomization (n=740)
Received standard
intervention as allocated (n=369)
Did not receive standard
intervention as allocated (n=0)
Follow-up (n=317)
Withdrawn 9 (n=52)
    Lost to follow-up (n=50)
    Risk category missing (n=2)
    Other (n=0)
Completed trial (n=315) Completed trial (n=338)
Follow-up (n=338)
Withdrawn 9 (n=28)
    Lost to follow-up (n=28)
    Risk category missing (n=0)
    Other (n=0)
Received trial
intervention as allocated (n=366)
Did not receive trial
intervention as allocated (n=5)
Figure 1 Trial proﬁle.
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Control group
Women randomized to the control clinic were seen by specialist
surgical staff who included a breast surgeon and breast care
nurse. A standard surgical protocol covered the following
components: (i) breast cancer surveillance (clinical breast exami-
nation and, for women aged over 35 years, a mammogram) and
advice on potential risk reducing strategies; (ii) surgical assess-
ment of individual breast cancer risk; (iii) the option of
entering the UK Tamoxifen Prevention Trial; and (iv) annual
surgical follow-up involving breast cancer surveillance and advice.
Referral for genetic counselling or presymptomatic genetic testing
was not offered. Surgical assessment of risk was based on non-
genetic information collected by the surgeon, including age,
reproductive history and minimal family history. This informa-
tion was presented to women by the breast surgeon in
generalized terms and was stratiﬁed by the surgeon into one of
three categories: low, moderate, or high risk.
Trial group
Women randomized to the trial clinic were seen by a multidis-
ciplinary team that combined clinical input from surgical staff
(components 1, 3 and 4 of the control intervention) with specia-
list genetic risk assessment and counselling provided by a clinical
geneticist and genetic nurse specialist. The surgical component of
the trial clinic did not include a surgical assessment of risk. The
genetic consultation involved genetic assessment of breast cancer
risk, education and counselling about familial breast cancer, and
the possible offer of presymptomatic testing for the BRCA1/2
gene. Assessment of risk was based on detailed family pedigree
data that were collected and analyzed by the geneticist using
the statistical model developed by Claus et al (1991). This
provides a risk estimate based on the number of breast cancer
cases in ﬁrst and second degree relatives, the age at diagnosis
of breast cancer in ﬁrst and second degree relatives and the
age of the presenting woman. The geneticist presented this infor-
mation to women as a residual lifetime risk of breast cancer,
expressed in percentage terms. Women were categorized by the
geneticist as low risk (less than 10% residual lifetime risk),
moderate risk (10–24%), or high risk (25% or more). Standar-
dized UK guidelines for categorizing genetic risk were not
available at the time this research was implemented. Chi-square
analysis indicated group equivalence in the number of partici-
pants stratiﬁed as low, moderate, or high risk (see Table 1).
Fifty women who were identiﬁed as high risk were offered muta-
tion searching in an affected relative. A further six high risk
women were not offered mutation searching because they did
not have an affected relative available to give a blood sample.
It was decided to retain this group in the statistical analysis since
excluding them did not alter the pattern of ﬁndings. Full details
of the clinical protocol are reported in Gray et al (2000).
Statistical analysis
A previous report of this trial indicated baseline comparability of
study groups (Brain et al, 2000b). Differences between risk groups
in demographic characteristics were examined using one-way
analysis of variance (ANOVA) or chi-square tests. A 2 (study
group)63 (risk group) repeated measures ANOVA was used to
calculate the signiﬁcance of group differences, changes over time,
and possible interaction effects for the primary outcomes. Demo-
graphic characteristics in which risk groups differed were
controlled and signiﬁcant effects were followed up with paired t-
tests or one-way ANOVA. The impact of study group and risk
information on satisfaction (general factorial ANOVA) and interest
in genetic testing (chi-square analysis) was examined. All results are
based on 653 participants who received risk information and
completed the questionnaires.
RESULTS
Sample characteristics
Table 1 displays descriptive statistics for the demographic charac-
teristics of risk groups.
Risk groups differed signiﬁcantly in education, age and family
history of breast cancer.
Impact of genetic risk assessment and counselling
Table 2 displays descriptive statistics for psychological characteris-
tics of risk groups at baseline and follow-up. Table 3 shows the
results of ANOVA.
State anxiety There were no signiﬁcant main or interaction
effects of study group and risk information. There was a signiﬁcant
main effect of time, suggesting an overall decrease in anxiety from
baseline to follow-up.
Breast cancer worry There was a signiﬁcant overall reduction in
cancer worry from baseline to follow-up and a signiﬁcant interac-
tion between risk information and time. Post-hoc analysis
indicated that cancer worry declined signiﬁcantly in women at
low risk (t(106)=5.92, P50.001) and moderate risk
(t(443)=12.13, P50.001), but not in those at high risk
(t(98)=1.67, P=0.10).
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Table 1 Demographic characteristics of low, moderate, and high risk groups
Trial Control
Characteristic Low risk Moderate risk High risk Low risk Moderate risk High risk F/w
2 d.f. P
No. patients (%) 53 (16) 229 (68) 56 (16) 54 (17) 218 (69) 43 (14) 1.18 2 0.56
Mean (+s.d.) age–year 52.88+7.75 41.63+8.52 33.71+8.19 48.63+10.25 40.45+9.13 39.17+7.33 34.78 5.642 0.000
Mean (+s.d.) relatives with breast cancer 2.06+0.86 2.34+1.29 3.14+1.55 2.02+1.03 2.28+1.16 3.23+1.43 10.36 5.643 0.000
Education–no. (%)
5Secondary level 26 (50) 67 (29) 16 (30) 22 (42) 49 (23) 14 (33) 19.16 5 0.002
5Secondary level 26 (50) 162 (71) 38 (70) 31 (58) 168 (77) 29 (67)
Marital status–no. (%)
Married/cohabiting 42 (81) 200 (87) 39 (71) 45 (83) 178 (82) 35 (81) 9.19 5 0.10
Not married/cohabiting 10 (19) 29 (13) 16 (29) 9 (17) 40 (18) 8 (19)
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mation. Post-hoc tests indicated that differences between risk
groups were signiﬁcant at baseline (F(2, 637)=17.48, P50.001)
and follow-up (F(2, 640)=128.56, P50.001). At both assessments,
perceived risk was signiﬁcantly higher in the high risk group
compared to the moderate or low risk groups, and was signiﬁ-
cantly higher in the moderate risk group compared to the low
risk group. The main effect of risk information was modiﬁed by
a signiﬁcant risk6time interaction. While perceived risk declined
signiﬁcantly in women at low risk (t(101)=10.78, P50.001) and
moderate risk (t(431)=13.27, P50.001), there was no signiﬁcant
change in perceived risk in those at high risk (t(96)=0.00,
P=1.00). Post hoc analysis of the signiﬁcant group6risk6time
interaction effect indicated that within the trial group, perceived
risk decreased signiﬁcantly in women at low risk (t(49)=6.90,
P50.001) and moderate risk (t(221)=11.83, P50.001). For high
risk women in the trial group, there was a marginally signiﬁcant
trend towards increased perceived risk (t(53)=71.72, P=0.09).
Within the control group there was a signiﬁcant decrease in
perceived risk for women at low risk (t(51)=8.35, P50.001) and
moderate risk (t(209)=7.03, P50.001), and a marginally signiﬁcant
trend towards reduced perceived risk in the high risk group
(t(42)=1.83, P=0.07).
Satisfaction There was a signiﬁcant main effect of risk informa-
tion, but not of study group, on instrumental satisfaction. Post-hoc
analysis indicated that women at high risk reported signiﬁcantly
lower instrumental satisfaction than women at low or moderate
risk, while those at moderate risk reported signiﬁcantly lower satis-
faction than those at low risk (F(2, 593)=13.80, P50.001). There
were no signiﬁcant main or interaction effects on procedural and
affective satisfaction.
Interest in genetic testing Although there was a signiﬁcant over-
all decline in interest (w
2=15.13, P=0.000, McNemar test), there
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Table 2 Psychological characteristics of low, moderate and high risk groups
Trial Control
Characteristic Low risk Moderate risk High risk Low risk Moderate risk High risk 95% CI
Mean (+s.d.) state anxiety
Baseline 36.53+12.68 36.21+11.23 35.95+9.92 36.43+11.44 35.99+10.70 38.27+12.57
Follow-up 34.03+8.95 34.48+11.12 35.14+12.29 32.96+10.70 33.11+9.97 35.44+12.44 73.59–2.35
Mean (+s.d.) cancer worry
Baseline 11.32+3.34 11.98+3.31 12.07+3.24 11.22+3.12 11.52+2.80 12.16+3.28
Follow-up 9.89+2.51 10.52+2.82 11.66+3.26 10.15+2.76 10.30+2.34 11.77+3.32 70.88–0.57
Mean (+s.d.) perceived risk
Baseline 6.70+1.15 7.42+1.25 7.87+1.06 7.19+1.33 7.22+1.13 8.00+1.15
Follow-up 5.46+1.23 6.45+1.11 8.11+1.06 5.62+1.19 6.65+0.91 7.70+1.28 71.04–0.29
Mean (+s.d.) instrumental satisfaction
Follow-up 10.70+1.52 10.22+1.79 9.41+2.04 10.69+1.55 10.03+1.68 9.31+1.78 70.16–0.25
Mean (+s.d.) procedural satisfaction
Follow-up 10.67+1.81 10.15+1.99 10.06+1.81 10.08+2.17 9.94+1.96 10.50+1.33 70.23–0.24
Mean (+s.d.) affective satisfaction
Follow-up 11.20+1.34 11.01+1.49 10.57+1.78 11.12+1.34 10.92+1.35 11.10+1.28 70.07–0.27
Interest in testing – baseline no. (%)
Yes 49 (92) 203 (89) 50 (89) 46 (85) 192 (88) 37 (86) 70.03–0.07
No 1 (2) 10 (4) 0 2 (4) 6 (3) 2 (5)
Unsure 3 (6) 15 (7) 6 (11) 6 (11) 20 (9) 4 (9)
Interest in testing – follow-up no. (%)
Yes 37 (88) 139 (82) 43 (78) 37 (84) 142 (79) 31 (82) 70.09–0.05
No 2 (5) 12 (7) 6 (11) 3 (7) 17 (10) 5 (13)
Unsure 3 (7) 19 (11) 6 (11) 4 (9) 20 (11) 2 (5)
Table 3 Analysis of variance for study group6risk on psychological out-
comes
a
Variable Effect F d.f. P
State anxiety Study group 0.05 1602 0.82
Risk 0.37 2602 0.69
Study group6risk 0.51 2602 0.60
Time 4.75 1602 0.03
Study group6time 2.66 1602 0.10
Risk6time 1.22 2602 0.30
Study group6risk6time 0.46 2602 0.63
Breast cancer worry Study group 0.002 1627 0.97
Risk 0.62 2627 0.54
Study group6risk 0.62 2627 0.54
Time 22.20 1627 0.000
Study group6time 0.60 1627 0.44
Risk6time 9.39 2627 0.000
Study group6risk6time 0.28 2627 0.76
Perceived risk Study group 0.75 1612 0.39
Risk 30.78 2612 0.000
Study group6risk 0.88 2612 0.42
Time 2.44 1612 0.12
Study group6time 1.52 1612 0.22
Risk6time 24.48 2612 0.000
Study group6risk6time 7.42 2612 0.001
Instrumental satisfaction Study group 0.09 1573 0.76
Risk 5.89 2573 0.003
Study group6risk 0.36 2573 0.70
Procedural satisfaction Study group 0.00 1542 0.97
Risk 0.99 2542 0.37
Study group6risk 1.57 2542 0.21
Affective satisfaction Study group 0.78 1564 0.38
RIsk 0.23 2564 0.80
Study group6risk 1.59 2564 0.20
aAdjusted for age, education and family history.
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(w
2(10)=6.15, P=0.80) or follow-up (w
2(10)=4.93, P=0.90).
DISCUSSION
An increasing number of women are seeking advice from health
care professionals in connection with a family history of breast
cancer. For a small subset of women, the family history strongly
indicates the presence of an inherited gene mutation; for the
majority of women who are at lower risk, the family history is
not linked to speciﬁc inherited factors and genetic testing will
not be of beneﬁt. The present study provides evidence regarding
appropriately structured service provision and effective use of
genetic resources for women who are at different levels of familial
breast cancer risk.
For most women who attend familial breast cancer clinics,
beliefs about increased personal risk may be moderated by the
provision of favourable risk information. The current ﬁndings
suggest that in women at lower risk, anxiety and cancer-related
concerns were reduced after receiving personal risk information
and there were high levels of satisfaction, regardless of whether
this information was based on a detailed genetic analysis.
Although some studies have shown no effect of providing risk
information on psychological outcomes (Kent et al, 2000; Lloyd
et al, 1996), this may reﬂect differences in the way that risk infor-
mation is communicated. Improved psychological outcomes may
be a function of services that not only provide speciﬁc risk infor-
mation, but also address patients’ emotional needs by offering
appropriate reassurance (Watson et al, 1998). Despite reduced
anxiety and perceived risk, women at lower risk remained inter-
ested in obtaining genetic testing. Although lower risk
individuals can gain useful information and support from cancer
genetics services without having genetic testing, the desire for test-
ing may be resistant to change and further exploration of this
phenomenon is necessary.
For the minority of women who are at high risk, providing
objective risk information may conﬁrm beliefs about increased
personal risk. The ﬁnding that general anxiety decreased in this
group suggests that risk information, even when unfavourable,
does not appear to generate clinically signiﬁcant anxiety (Cull
et al, 1999; Hopwood et al, 1998; Lerman et al, 1996). However,
women at high risk remained concerned about breast cancer and
were less satisﬁed with their consultation, regardless of study
group. Hence unfavourable risk information may not lead to
clinical anxiety, but persistent worries about breast cancer may
compromise quality of life for women who already recognize that
they are at increased genetic risk. It is possible that high risk
women were kept in a state of uncertainty because genetic test
results were not available to them at the time of this research.
Although it was not within the scope of the current study to
examine the impact of receiving genetic test results, prior
research suggests that receiving test results may confer important
psychological beneﬁts by alleviating chronic worry and uncer-
tainty about health in relation to breast cancer (Broadstock et
al, 2000; Lerman et al, 1996, 1998). There was some evidence
for an effect of study group on perceptions of personal risk in
high risk women, suggesting that detailed genetic information
and the offer of testing may generate increased concerns about
risk. It was not possible to examine psychological impact sepa-
rately for the small number of high risk women who could
not be offered testing due to the absence of an affected relative
available to give a blood sample for mutation searching. Further
research is needed to explore psychological outcomes in high risk
women who receive genetic test results compared with those who
are awaiting results as well as those who cannot be offered test-
ing.
It is acknowledged that the small effect of study group on
perceived risk in high risk women may have reﬂected differences
in methods of classifying and communicating risk that were used
in the intervention and control arms of the trial. However, there
did not appear to be an effect of different risk assignment methods
on women at low or moderate risk, who were reassured regardless
of study group. Further controlled studies are necessary to compare
the reliability of different methods of assessing familial breast
cancer risk.
The present ﬁndings have important resource implications.
The multidisciplinary cancer genetics clinic at tertiary care level
is a suitable environment for providing genetic information,
counselling and testing to high risk families, but not all women
with a family history need to be referred. Breast care specialists
other than geneticists might provide initial assessments of risk
for breast cancer, reassuring women at lower risk and targeting
those at high risk for referral to specialist genetics clinics. In a
report to the Department of Health on UK cancer genetic
services (1998), recommendations were made for a ﬁltered
approach to service provision corresponding to the three levels
of care described in the Calman-Hine report (1995). These are
general practice (primary care), risk assessment at cancer unit
level (secondary care), and specialist genetic services involving
genetic counselling and, where appropriate, presymptomatic
genetic testing at cancer centre level (tertiary care). This ﬁltered
approach is a vital ﬁrst step in developing appropriate service
structures and the selective use of specialist genetic resources
in breast cancer and, increasingly, other common inherited
cancers.
It is possible that the current ﬁndings reﬂect the high level of
expertise of specialist staff who were involved in the project, which
led to enhanced care in the control arm. It remains to be seen
whether the ﬁndings will generalize to the community setting. Over
the next few years, it is likely that initial genetic risk assessment will
be conducted in different settings by primary care and, increas-
ingly, nurse specialist staff. Further research must be undertaken
to explore their potential role in the appropriate identiﬁcation
and management of at-risk women, the effectiveness of different
strategies for assessing and communicating genetic risk information
(Emery et al, 2000) and the acceptability of a ﬁltered service struc-
ture to patients and providers. Recent consensus guidelines for
assessing and stratifying familial breast cancer risk must be incor-
porated into clinical practice in order to minimize potential
variation between the different health care professionals who are
likely to be involved in the management of this patient group
(British Association of Surgical Oncology Guidelines, 1998; Eccles
et al, 2000). The education and training needs of health profes-
sionals must also be identiﬁed (Watson et al, 1999), since they
may be required to not only communicate accurate genetic risk
information but also address the psychological needs and concerns
of individuals who approach them with concerns about a family
history of cancer.
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